Company intelligence / Profile preview

Dynamic Cell Therapies

Watertown, Massachusetts, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

DCT is developing novel CAR T-cell technologies that have demonstrated superiority to FDA-approved CAR T-cells in animal models. Their proprietary CAR T-cells aim to improve safety and efficacy for patients with hematological cancers. The company's lead product, DCT-CAR100 for multiple myeloma, has reached IND Application stage[1][2].

Therapeutic areas: Oncology
Modalities: CAR T-cell therapiesCytokines
Industry: Biotech

Partnerships

Multiple Myeloma Research Foundation (MMRF)

Beyond the preview

Go deeper on Dynamic Cell Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynamic Cell Therapies.

Explore the full profile